Gold Prices Slip as Stronger Dollar and Iran Peace Talk Uncertainty Weigh on Market 
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Yen Stays Near Intervention Zone as Iran Conflict Supports U.S. Dollar 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Canada and Germany Advance Major LNG Supply Partnership 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
Australia Urged to Simplify Regulations to Revive IPO Market and Boost Innovation 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Australia Inflation Cools in April as Fuel Prices Ease, But Core CPI Remains Sticky 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
